IGFBP-rP1 acts as a potential tumor suppressor via the suppression of ERK signaling pathway in endometrial cancer cells

YU MA1, JUE JIANG2, YAN ZHANG3, YI DING2, TING XU2 and BINGJIAN LU4

1Department of Clinical Laboratory, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006; 2Institute of Bioinformatics, School of Agriculture and Biological Technology, Zhejiang University, Hangzhou, Zhejiang 310029; 3Department of Clinical Laboratory, Yiwu Hospital, School of Medicine, Zhejiang University, Yiwu, Zhejiang 322000; 4Department of Surgical Pathology, The Affiliated Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China

Received June 15, 2016; Accepted April 12, 2017

DOI: 10.3892/mmr.2017.6713

Abstract. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor-suppressor gene in various cancers. However, its biological role and underlying mechanism has not been well investigated in endometrial cancer yet. The aim of the present study aimed to investigate the role and underlying molecular mechanisms of IGFBP-rP1 in endometrial cancer cells in vitro. The authors used transfection of IGFBP-rP1 or small interfering (si)RNA in endometrial cancer HEC-1A or Ishikawa cells, respectively. Biological functional alterations, such as cell growth and cell cycle were analyzed in endometrial cancer cells, combined with the use of PD98059. A panel of proteins including phospho-retinoblastoma (p-RB) and p-extracellular signal-regulated kinase (ERK)/ERK were detected by western blot analysis. It was observed that IGFBP-rP1 transfection inhibited cell growth, and induced G1 phase arrest and cellular senescence in HEC-1A cells while gene silencing presented the adverse functional changes. Moreover, p-RB and p-ERK were significantly downregulated or upregulated in HEC-1A-IGFBP-rP1 cells or Ishikawa-siRNA (IGFBP-rP1) compared with control cells, respectively. These observations were reinforced in endometrial cancer cells by PD98059 treatment. The authors conclude that IGFBP-rP1 acts as a potential tumor suppressor via the suppression of the ERK signaling pathway in endometrial cancer cells. These findings suggested that IGFBP-rP1 may serve as a potential therapeutic target for cancer intervention in the future.

Introduction

The incidence of endometrial carcinoma increased steadily in the last decade (1). It has become the second most common gynecologic cancer in China (2). A substantial body of epidemiologic data indicated that metabolic syndrome, characterized by obesity, hypertension, and diabetes is closely associated with endometrial carcinoma (3). As insulin resistance is the hallmark of metabolic syndrome, more attention has been focused on the relationship between insulin-like growth factors system and endometrial carcinoma (4,5).

The insulin-like growth factor binding protein (IGFBP) superfamily serves essential roles in the IGF system by modulating the bioavailability of IGFs and/or insulin (6-8). IGFBP-related protein 1 (rP1) is a secreted protein belonging to the IGFBP superfamily. IGFBP-rP1 may be associated with insulin resistance by its high affinity with insulin (6,9). A previous study of the authors indicated that elevated IGFBP-rP1 was associated with increased endometrial cancer risk (10). Insulin can promote cell growth in vitro (11). Accordingly, IGFBP-rP1 can function as a tumor-suppressor gene in various cancers including colorectal cancer and breast cancer (12-17). However, the biological role of IGFBP-rP1 in endometrial cancer has not been investigated yet. In the present study, the authors attempted to explore the role and underlying molecular mechanisms of IGFBP-rP1 in endometrial cancer cells in vitro.

Materials and methods

Materials. Human endometrial cancer cell lines Ishikawa and HEC-1A were donated by the Key Laboratory of Women's Reproductive Health of Zhejiang Province (Hangzhou, China). All cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% (v/v) heat-inactivated bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and grown at 37˚C in an atmosphere of 95% air and 5% CO2. The mouse anti-human IGFBP-rP1 monoclonal antibody was from R&D Systems, Inc. (cat no. MAB1334; 1:500; Minneapolis, MN, USA). The rabbit anti-human polyclonal antibodies, β-actin (cat no. 20536-1-AP; 1:1,000), Rb (cat no. 17218-1-AP; 1:800),...
p16 (cat no. 10883-1-AP; 1:500), p21 (cat no. 10355-1-AP; 1:500), p53 (cat no. 10442-1-AP; 1:500) and extracellular signal-regulated kinase (ERK)1/2 (cat no. 16443-1-AP; 1:1,000) were from ProteinTech Group, Inc. (Chicago, IL, USA). The rabbit anti-human antibody, phospho-retinoblastoma (Thr826; p-RB; cat no. AF0030; 1:1,000) was from Affinity Biosciences (Cincinnati, OH, USA). Goat anti-human polyclonal antibody p-ERK (Tyr 204; cat no. sc-7976; 1:800) was from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The Cell Counting Kit (CCK)-8 was from Dojindo Molecular Technologies, Inc. (Kumamoto, Japan). PD98059 was from Selleck Chemicals (Houston, TX, USA).

Cell culture, transfection and small interfering (si)RNA treatment. pcDNA 3.1 (IGFBP-rP1) containing full-length IGFBP-rP1 coding sequence was donated by Department of Pathology, School of Medicine, Zhejiang University (Hangzhou, China). DNA sequencing analysis confirmed the fidelity of the constructs. Transfection of pcDNA 3.1 (IGFBP-rP1) into HEC-1A cells, which did not express IGFBP-rP1, was performed using Lipofectamine 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. HEC-1A cells with an empty vector (HEC-1A-EV), produced by transducing with pcDNA 3.1/myc-His (B) alone, was used as a negative control. Stable transfectants (HEC-1A-IGFBP-rP1) were obtained following selection with 500 µg/ml G418 for 2 weeks.

Three different sets of siRNAs (IGFBP-rP1 siRNA) and irrelevant controls (negative control) (both from Invitrogen; Thermo Fisher Scientific, Inc.) were transiently transfected into Ishikawa cells (with IGFBP-rP1 expression) in 6-well culture dishes (1x10^5 cells) using Lipofectamine 2000 transfection reagent, according to the manufacturer's protocol. The IGFBP-rP1 siRNA#1 targets against the exon 5 of IGFBP-rP1 (5'-AAUCCACUAACAUUUAGUUTT-3', 5'-AACUAAGUGAUUGGAGUUGT-3'), IGFBP-rP1 siRNA#2 against the exon 2 (5'-CAGGUUGAUUGCGUUGAGGUCATT-3', 5'-UGACCAUCAAGCUCUAGACCU GTT-3') and IGFBP7 siRNA#3 against the exon 4 (5'-GCGGGAAUAUGUGGCCAUGCACTT-3', 5'-AUUCCAU CGCUCUAUUACUCAGCTT-3'). The Ishikawa-siRNA (IGFBP-rP1) cells were further cultured for 48 h until use.

Western blot analysis. Cells were separated from 6-well plates by phosphate-buffered saline (PBS) containing 0.25% trypsin-EDTA and washed 3 times with PBS, then lysed in 1 ml lysis buffer consisting of 7 M urea, 2 M thiourea, 4% CHAPS, 65 mM DTT and 0.2% Bio-lyte (pH 3-10; cat no. 1632094; Bio-Rad Laboratories, Inc., Hercules, CA, USA) by sonication on ice. The lysates were centrifuged at 13,500 x g for 1 h at 4°C. Subsequently, the protein concentration of the supernatants was measured by the Bradford method (Bradford Protein Assay kit, cat no. PC0010; Solarbio Science & Technology Company, Beijing, China), and aliquots of the protein samples were stored at -80°C. Aliquots of protein extracts (50 µg) were separated on an 8% SDS-PAGE according to the protein molecular weight. Subsequently, the protein was electrophoretically transferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Inc.). Following blocking with TBS-Tween-20 (0.2%; TBST) containing 5% non-fat milk, the membranes were incubated with primary antibodies (see above) in TBST overnight at 4°C, followed by peroxidase-conjugated second antibody [goat anti-mouse IgG (H+L); cat no. 626520; 1:5,000; Thermo Fisher Scientific, Inc.; goat anti-rabbit IgG (H+L); cat no. 31460; 1:5,000; Thermo Fisher Scientific, Inc.; peroxidase-conjugated affinity purified rabbit anti-goat IgG (H+L); cat no. SA00011-4; 1:5,000; ProteinTech Group, Inc.] diluted in 1:5,000 in TBST for 1 h at room temperature. Finally, blots were developed with the Odyssey system version 3 (LI-COR Biosciences, Lincoln, NE, USA). As a control for equal protein loading, blots were re-stained using anti-β-actin antibody.

Cell proliferation assay. Cell proliferation of stable HEC-1A and Ishikawa cells was measured using the CCK-8 (Dojindo Molecular Technologies, Inc.). In brief, cells were plated in 96-well plates at 5x10^3/well. A volume of 10 µl CCK-8 solutions were added during the last 4 h of the culture. Optical density of the wells was measured at 450 nm using the Multitsa FC microplate reader (Thermo Fisher Scientific, Inc.).

Flow cytometry assay. Cells were collected at 48 h following treatment for DNA content analysis. The adherent cells were harvested with PBS containing 0.25% trypsin-EDTA. The harvested cells were washed twice with PBS. Then the cells were treated with PBS containing 0.25 mg/ml RNase at 37°C for 15 min and incubated with 50 mg/ml propidium iodide at 4°C for 15 min in the dark. The stained cells were analyzed by flow cytometry (Beckman Coulter, Inc., Brea, CA, USA) with Cell Quest software version 6.0 (BD Biosciences, Franklin Lakes, NJ, USA).

Senescence-associated β-galactosidase (SA-β-gal) staining. The senescence status of cells was verified by in situ staining for SA-β-galactosidase, as described previously (18). Briefly, cells that were grown on 60 mm cell culture dishes were washed three times with PBS and fixed with 2% formaldehyde/0.2% glutaraldehyde in PBS for 10 min. Then, they were washed again and incubated with β-galactosidase substrate staining solution [150 mM NaCl, 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 40 mM citric acid and 12 mM sodium phosphate; pH 6.0; containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-β-d-galactoside (X-gal)] for 24 h at 37°C. The cells were washed with PBS. Greenish cytoplasmic staining was regarded as positive. The positive cells were counted in three high power fields with a diameter of 4.4 mm (Leica DMR 2000; Leica Microsystems GmbH, Wetzlar, Germany) and recorded as a percentage of positive cells to the total. The experiment was conducted in triplicate.

Statistical analysis. Statistical analysis was performed using SPSS software (version, 19.0; IBM SPSS, Armonk, NY, USA) for Windows. The paired-sample t-test was conducted to compare protein levels and other data between groups. P<0.05 was considered to indicate a statistically significant difference.

Results

IGFBP-rP1 inhibited cell growth and induced cellular senescence in endometrial carcinoma cells. Expression of
IGFBP-rP1 was detected by western blotting following cell transfection in HEC-1A or significantly inhibited by siRNA in Ishikawa cells (Fig. 1A and B). IGFBP-rP1 siRNA (#3) presented the highest inhibitory effects and was used in all subsequent experiments (Fig. 1B). IGFBP-rP1 transfection suppressed the growth of HEC-1A cells whereas IGFBP-rP1 silence promoted the growth of Ishikawa cells (Fig. 1C and D). IGFBP-rP1 induced cell cycle arrest by demonstrating a higher proportion of cells in the G1 phase in the HEC-1A-IGFBP-rP1 cells (77.59±1.275%) than in the controls (66.54±0.68%; P<0.05) by flow cytometry with propidium iodide staining (Fig. 1E). In contrast, IGFBP-rP1 silence promoted cell cycle in Ishikawa cells as indicated by decreased cells in the G1 phase (52.76±0.88% in IGFBP-rP1-siRNA cells vs. 62.17±1.96% in control cells, P<0.05; Fig. 1F), and increased cells in the S phase (36.45±2.89% in IGFBP-rP1-siRNA cells vs. 29.22±0.99% in control cells; P<0.05).

SA-β-galactosidase staining, a golden standard for cellular senescence, indicated that HEC-1A-IGFBP-rP1 cells had a higher proportion of SA-β-galactosidase positive cells (34.04±3.24%) than the control cells (17.48±0.63%; P<0.01; Fig. 2A). On the contrary, SA-β-galactosidase activity significantly decreased in Ishikawa-siRNA (IGFBP-rP1) cells (6.27±1.32%) compared with negative controls (12.57±0.63%; P<0.05; Fig. 2B and C). Moreover, p-RB, a key regulator in cellular senescence, was significantly reduced in HEC-1A-IGFBP-rP1 cells than control cells (2.64±0.21% vs. 12.95±0.31%; P<0.01) while other senescence-related proteins, p21, p53 and p16, increased ~four-fold, 55-fold and 24-fold in HEC-1A-IGFBP-rP1, respectively (P<0.01; Fig. 3A). In contrast, Ishikawa-siRNA (IGFBP-rP1) cells presented...
a 2.8-fold increased expression of p-RB (P<0.01) and a decrease level of p16, p21 and p53 protein than control cells (p16, 1.28±0.17% vs. 9.15±0.59%; P<0.01; p53, 0.27±0.05% vs. 6.11±0.48%; P<0.01; p21, 6.09±0.31% vs. 8.88±0.56%; P<0.05; Fig. 3B). The levels of total RB protein demonstrated no significant changes between transfectants and control cells.

The suppression of p-ERK/ERK pathway is associated with the biological functions of IGFBP-rP1. To explore the underlying cell growth inhibition mechanisms of IGFBP-rP1, the authors analyzed the activities of the ERK pathway in endometrial cells with forced or deprived IGFBP-rP1 expression. A 97.5% reduction of p-ERK was present in HEC-1A-IGFBP-rP1 cells vs. control cells (P<0.01) and a 3.21-fold increase in Ishikawa-siRNA (IGFBP-rP1) cells vs. control cells (P<0.01; Fig. 3). The total ERK protein levels remained stable between transfectants and control cells.

PD98059, an inhibitor of the MAP/ERK kinase (MEK)/ERK pathway, significantly suppressed cell proliferation and induced cellular senescence in endometrial cancer cells (Figs. 1C and D and 2A and B). Moreover, HEC-1A-IGFBP-rP1 cells with PD98059 treatment reported an additive effect on cell growth inhibition compared to control cells with PD98059 treatment alone or HEC-1A-IGFBP-rP1 (Fig. 1C and D). G1 phase arrest was more apparent in HEC-1A-IGFBP-rP1 cells with PD98059 treatment compared to control cells with PD98059 treatment or IGFBP-rP1 (cells in G1 phase: PD98059+IGFBP-rP1, 80.27±1.165% vs. PD98059, 72.76±0.35% or IGFBP-rP1, 77.59±1.275%; P<0.01; cells in S phase: PD98059+IGFBP-rP1, 15.45±0.86% vs. PD98059, 16.68±1.06% or IGFBP-rP1, 17.93±1.41%; P<0.05; Fig. 1E). In Ishikawa cells, IGFBP-rP1-siRNA alleviated G1 phase arrest of PD98059 treatment (cells in G1 phase: IGFBP-rP1-siRNA+PD98059, 60.02±0.84% vs. PD98059, 67.12±1.70%; P<0.01; Fig. 1F).

HEC-1A-IGFBP-rP1 cells with PD98059 treatment presented more SA-β-galactosidase positive cells than HEC-1A with PD98059 treatment (81.11±2.94% vs. 57.89±2.44%; P<0.01) or HEC-1A-IGFBP-rP1 cells (81.11±2.94% vs. 34.04±3.24%; P<0.01; Fig. 2C). SA-β-galactosidase activity significantly decreased in Ishikawa-siRNA (IGFBP-rP1) cells with PD98059 compared with controls (PD98059 alone, 25.80±1.15% vs.
IGFBP-rP1 can significantly downregulate p-RB expression, and upregulate the expression of p16 and p53 in both HEC-1A and Ishikawa cells (P<0.01; Fig. 3), but did not influence the level of total RB protein in endometrial cancer cells. PD98059 presented a lower level of p-RB and p-ERK (p-RB, 1.62±0.12% vs. 3.08±0.29%; P<0.01; p-ERK, 1.44±0.24% vs. 5.39±0.11%; P<0.01), and upregulated expression of the p16, p53 and p21 proteins in HEC-1A-IGFBP-rP1 cells than in control HEC-1A cells (p16, 25.20±0.09% vs. 21.62±0.67%; P<0.05; p53, 23.96±0.01% vs. 12.31±0.23%; P<0.05; p21, 26.55±0.59% vs. 5.70±0.28%; P<0.01). On the contrary, PD98059 significantly upregulated the expression of p-RB and p-ERK (p-RB, 14.90±0.21% vs. 1.75±0.08%; P<0.01; p-ERK, 14.89±0.16% vs. 2.39±0.09%; P<0.01), and significantly downregulated the expressions of p16, p53 and p21 in Ishikawa-siRNA (IGFBP-rP1) cells than in control Ishikawa cells (p16, 17.7±0.46% vs. 19.7±0.31%; P<0.05; p53, 7.76±0.11% vs. 26.34±0.54%; P<0.01; p21, 9.42±0.09% vs. 25.98±0.12%; P<0.01).

### Discussion

Accumulative evidence indicates that metabolic syndrome is closely associated with endometrial carcinoma (3,19,20). Insulin resistance remains the pillar of metabolic syndrome. The dysfunction of the insulin/IGF/IGFBP axis serves essential roles in insulin resistance. Numerous research has been focused on the role of the insulin/IGF/IGFBPs axis in metabolic syndrome and related diseases including endometrial carcinoma (4-8). IGFBP-rP1 is a secreted factor belonging to the IGFBP family. IGFBP-rP1 may play a tumor-suppressor role in various tumors (12-17), but its biological functions in endometrial carcinoma have not been fully investigated yet. In the present study, the authors found that IGFBP-rP1 can inhibit cell proliferation and induce cell senescence in endometrial cancer cell lines. These findings supported the idea that IGFBP-rP1 functioned as a tumor suppressor in endometrial carcinoma.

IGFBP-rP1, also known as MAC25 or IGFBP7, was initially isolated from the senescent breast cancer cells (21). A number of studies validated the role of IGFBP-rP1 in cellular senescence in various carcinomas (13-15,17,22). The p-RB/p53 pathway is well known to be the classical pathway in the process of cellular senescence (23-26). In the current study, IGFBP-rP1-transfection was shown to downregulate the expression of p-RB and upregulate the expression of p53, p16 and p21 in endometrial carcinoma cells, while IGFBP-rP1 silence demonstrated the opposite roles. These results clearly demonstrated that IGFBP-rP1 can activate key factors, such as p-RB, p53 and p21, in the p-RB/p53 pathway to trigger cellular senescence in endometrial carcinoma. These results are in-keeping with several reports from other cancers (13-15,17,22). Wajapeeyee et al (22) reported that IGFBP7, had a central role in BRAFV600E-mediated senescence and apoptosis in melanoma cells. Early work of the authors indicated that IGFBP-rP1 could promote cellular senescence in colorectal cancer cells (17).

IGFBP-rP1 binds to IGF-1 and IGF-2 with 100-fold lower affinity than IGFBP1 to IGFBP6, which infers that IGFBP-rP1 may act in both an IGF-dependent and an IGF-independent way (9). The IGF-dependent route is well established as the central role in insulin resistance by the activation of the PI3K/AKT signaling pathway. In contrast, the IGF-independent manner of IGFBP-rP1 remains largely unknown at present. ERK is generally considered to be anti-apoptotic, and ERK signaling pathway is essential to cellular growth and survival. Sustained activation of ERK1/ERK2 is necessary for G1- to S-phase progression and is associated with induction of positive regulators of the cell cycle and inactivation of anti-proliferative genes (27). In the present study, the authors’ results clearly demonstrate that IGFBP-rP1 functions through inhibition of the ERK signaling pathway. IGFBP-rP1 could downregulate the p-ERK protein. The combination of IGFBP-rP1 and PD98059, an inhibitor of the MEK/ERK pathway, had synergistic effects on cell proliferation suppression and cellular senescence in endometrial cancer cells. Moreover, IGFBP-rP1-siRNA alleviated cell growth inhibition and cellular senescence, which were caused by the blockage of ERK signaling pathway by PD98059 in endometrial cancer cells. A previous study in breast cancer cells also indicated that IGFBP-7 (IGFBP-rP1) strongly suppressed the phosphorylation of ERK1/2, suggesting that IGFBP-7 mediates its anti-proliferative effects through negative feedback signaling (28). In addition, Wajapeeyee et al (22) indicated that IGFBP7 induced senescence and apoptosis through autocrine/paracrine pathways to inhibit BRAF-MEK-ERK signaling in BRAFV600E-expressing melanoma cells.

In summary, the present study demonstrated that IGFBP-rP1 acts as a potential tumor suppressor via the suppression of the ERK signaling pathway in endometrial cancer cells. These findings suggested that IGFBP-rP1 may be a potential therapeutic target for cancer intervention. However, further investigation is required to clarify the detailing of the IGFBP-rP1 and ERK networks and their roles in vivo.

### Acknowledgments

The present work was supported by grants from the National Natural Science Foundations of China (grant nos. 81202067 and 81372790) and the Zhejiang Provincial Natural Science Foundation of China (grant no. LQ12H16008).

### References


